权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

HIV-1 and Alzheimer’s disease: Comorbidity

HIV-1 和阿尔茨海默病：合并症

基本信息

批准号：
10760712
负责人：
Khalid Benamar
金额：
$ 40.7万
依托单位：
UNIVERSITY OF TEXAS RIO GRANDE VALLEY
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-09-01 至 2025-08-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10760712
关键词：
Acceleration Address Adult Affect Age Alzheimer&apos s Disease Alzheimer&apos s disease related dementia Amyloid Amyloid beta-Protein Animal Model Area Behavioral Biochemistry Brain Case Study Central Nervous System Infections Characteristics Cognitive Cognitive deficits Data Dementia Disease Progression Economics Goals HIV HIV Infections HIV Seropositivity HIV diagnosis HIV-1 HIV-associated neurocognitive disorder Health Human Impaired cognition Individual Knock-in Mouse Knowledge Longitudinal Studies Medical Care Costs Modeling Molecular Biology Mus Neurodegenerative Disorders Neurofibrillary Tangles Onset of illness Outcome Outcome Measure Pathology Persons Population Reporting Research Research Personnel Sample Size Senile Plaques Synapses Testing Therapeutic Studies Transgenic Mice Treatment Protocols World Health Organization age related neurodegeneration aged antiretroviral therapy biological systems cognitive function comorbidity early onset interdisciplinary approach mouse model nervous system disorder neurodegenerative dementia neuropathology pharmacologic public health relevance tau Proteins tool

项目摘要

PROJECT SUMMARY/ABSTRACT Alzheimer’s disease (AD) is a devastating neurodegenerative disorder characterized by a progressive impairment of cognitive functions. The World Health Organization estimates that 55 million people worldwide live with dementia, of which two-thirds are due to AD, and this number is expected to increase to 131.5 million by 2050. In 2021 an estimated 38.4 million people were living with Human immunodeficiency virus-1 (HIV). HIV- associated neurocognitive disorder (HAND) is a common primary neurological disorder associated with HIV infection of the central nervous system, despite successful virologic control with combination antiretroviral therapy (cART). 50% of the US HIV-positive population is aged 50 years or older, mainly due to the successful treatment regimens helping HIV-positive adults survive for decades with HIV. There is concern AD may become prevalent with an earlier onset of cognitive deficit or accelerate the disease progression. Currently, there are no scientific data to support or oppose if HIV can affect the onset and progression of AD cognitive decline. To address this critical knowledge gap and test the hypothesis, we will use two AD mouse models, human amyloid knock-in mouse (hAβKI) and Tau transgenic mice models infected with chimeric HIV (EcoHIV). Our central hypothesis is that HIV promotes the onset of cognitive decline in AD mice models. We will use a multidisciplinary approach to test the hypothesis, including behavioral, pharmacological, molecular biology, and biochemistry. Aim 1. We will perform the first longitudinal studies using 2 AD mouse models, an HIV model that mimics PLWH, and multiple outcome measures capturing several AD-associated cognitive dysfunctions to determine if EcoHIV accelerates the onset of cognitive decline in AD mice. We will also explore the potential mechanism (e.g., Aβ disposition). This application addresses critical health conditions and a new challenge that looms as individuals living with HIV age and reach age-related neurodegenerative diseases: HIV and AD comorbidity. A potential outcome will be that EcoHIV promotes the onset of cognitive decline in AD mice. This knowledge has the potential to advance the field of HIV and AD comorbidity because it will show that HIV and AD are not independent health conditions, but when they are comorbid, HIV can interfere with AD cognitive decline onset.

项目总结/文摘